The current adjunct pharmacotherapy options for weight loss is discussed by Dr W Timothy Garvey (University of Alabama at Birmingham, Birmingham, AL, USA). Semaglutide being an example, which is approved for the treatment of type 2 diabetes.
Dr W Timothy Garvey presented an abstract entitled ‘Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Beyond lifestyle interventions, what are the current adjunct pharmacotherapy options for achieving weight loss? (0:27)
- Semaglutide is approved for the treatment of type 2 diabetes – what is already known about its impact on weight loss? (1:06)
Disclosures: W Timothy Garvey is on the advisory board for Alnam, Boehringer-Ingelheim, Eli Lilly, Fractyl, JAZZ Pharmaceuticals, Novo Nordisk and Pfizer. W Timothy Garvey has received grant/research support from Eli Lilly, Epitomee, Novo Nordisk and Pfizer. All clinical trials were sponsored by the University of Alabama at Birmingham.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Obesity
Osama Hamdy, ADA 2022: Phenotypes and target options in diabetes
The 82nd ADA meeting, June 3-7, 2022, hosted a debate surrounding targets for diabetes management being body weight or glycaemic control. Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) discusses the array of phenotypes with which diabetes presents, with precision medicine being the ultimate goal. Questions: What were your highlights of this year’s meeting? […]
Osama Hamdy, ADA 2022: Tirzepatide for obesity in the SURMOUNT-1 study and remission in type 2 diabetes
The results of SURMOUNT-1, the first phase 3 trial with the novel GIP/GLP-1 receptor agonist tirzepatide for obesity, is discussed by Dr Osama Hamdy (Joslin Diabetes Center, Boston, MA, USA) as well as key data on remission, a key theme at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022. Questions: What were the […]
W Timothy Garvey, ADA 2022: Semaglutide for type 2 diabetes, the 10-year risk in patients with obesity
A risk stratification tool has been developed that enables the prediction of the 10-year risk of patients with obesity developing type 2 diabetes. Dr W Timothy Garvey (University of Alabama at Birmingham, Birmingham, AL, USA) discusses the tool, named Cardiometabolic Disease Scoring, the impact of semaglutide on the risk of developing type 2 diabetes and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!